TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attends BIO International Convention during 6/3~6/6 and will be in Taiwan Pavilon (Booth: 1917). ImmunAdd developed a synthetic saponin IA-05 which can be synthesized in large scale and manufactured in GMP facility. IA-05 is formulated in aqueous […]
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, proudly announced that our funder and CEO, Dr. Pi-Hui Liang, awarded “Outstanding Research Award”. Dr. Pi-Hui Liang leads her team, leaning on their erudite knowledge in medical chemistry, drug formulation, and regulations, to work on developing therapies […]
TAIPEI, Taiwan Jan 18, 2024 – IP Australia has granted ImmunAdd the patent on the synthetic saponin molecules. Innovation for Better Health We are ImmunAdd.
TAIPEI, Taiwan Jan 13, 2024 – Canadian Intellectual Property Office has granted ImmunAdd the patent on the synthetic saponin molecules. “Innovation for Better Health” We are ImmunAdd.
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster […]
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the BIO International Convention conference in San Diego, California, on June 13-16. Founder of ImmunAdd, Pi-Hui Liang, said, “My team and I are delighted to attend the BIO conference in San Diego, where we will show our […]
TAIPEI, Taiwan Jun 28, 2022 – Taiwan Intellectual Property Office has granted ImmunAdd the patent on the synthetic saponin molecules. Innovation for Better Health We are ImmunAdd.
Our team was awarded the 18th National Award in the Academic Research for “the Discovery of IA05 as a Novel Saponin Adjuvant for Therapeutic Vaccine.” Our proprietary next generation saponin-based adjuvant platform has been awarded in the 18th National Award in the Academic Research.
- 1
- 2